Graybug Vision, Inc. (NASDAQ:GRAY – Get Free Report) shares traded down 3% on Wednesday . The stock traded as low as $2.53 and last traded at $2.56. 19,574 shares were traded during trading, an increase of 804% from the average session volume of 2,165 shares. The stock had previously closed at $2.64.
Graybug Vision Stock Down 3.0 %
The company has a market capitalization of $4.02 million, a PE ratio of -1.48 and a beta of 1.20. The stock’s fifty day moving average price is $2.97 and its two-hundred day moving average price is $3.73.
Graybug Vision Company Profile
Graybug Vision, Inc, a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema.
Recommended Stories
- Five stocks we like better than Graybug Vision
- Utilities Stocks Explained – How and Why to Invest in Utilities
- 3 Must-Have ETFs Set to Dominate This Quarter
- What is Put Option Volume?
- Seeking Stability? These 3 Stocks Offer Strong Potential
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Trade War Bargain Stocks: Top 3 Picks Too Good to Pass Up
Receive News & Ratings for Graybug Vision Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Graybug Vision and related companies with MarketBeat.com's FREE daily email newsletter.
